Prezalumab

N/A

Report date: 2023/08/13 20:00:34

Base Information

Drug NamePrezalumab
Drug Alias Nameprezalumabum普瑞鲁单抗普瑞芦人单抗AMG-557/MEDI5872Anti-B7RP1-MAb +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionICOS ligand inhibitors
TargetsICOS ligand
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus Erythematosus, CutaneousSjogren's Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune LlcAmgen Inc
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicLupus Erythematosus, CutaneousSjogren's Syndrome +[4] 

Other Information

ATC CodeN/A
Related LinksN/A